Endo Beats Q4 Views, Inks Boston Scientific Deal

By | March 2, 2015

Scalper1 News

Specialty drugmaker Endo International (ENDP) beat analysts’ Q4 estimates and announced the $1.65 billion sale of its urology-device business Monday, sending the stock to a new high. Endo said earnings rose 21% over the year-earlier quarter to $1.16 a share, beating analysts’ consensus by 4 cents, according to Thomson Reuters. Revenue climbed 37% to $800 million, about $20 million above consensus. For the year, sales rose 10% to $2.88 billion, Scalper1 News

Scalper1 News